OVID Ovid Therapeutics Inc.
Financings ·
Ovid Therapeutics agreed to a private placement of convertible preferred stock and warrants with initial gross proceeds of about $80.8 million and up to $175.1 million in total. The preferred cannot convert until stockholders approve more shares, and the same day the company reported Phase 1 data from 68 healthy volunteers, with the CEO among the investors.
Nasdaq told Ovid on September 11, 2025 that it again meets the $1.00 minimum bid price, but the company's notice does not say how it got back above that level.
Nasdaq says Ovid's average closing bid price was below $1.00 for 31 consecutive trading days. The company has 180 calendar days to regain compliance and says its Nasdaq listing is unaffected for now.
Ovid Therapeutics Inc. is a biopharmaceutical company developing small molecule medicines for brain disorders. Its programs seek to address fundamental biological targets in the brain implicated in neuronal hyperexcitability, such as neurotransmitters and dysregulated ion channels. The company says it has in-licensed and clinically developed potential medicines that may offer first-in-class or best-in-class mechanisms of action. Its clinical programs are indicated for drug-resistant focal onset seizures, developmental and epileptic encephalopathies, including tuberous sclerosis complex seizures and infantile spasms, psychosis associated with Parkinson's disease and Lewy body dementia, and schizophrenia. Its KCC2 direct activator portfolio has potential applications across psychoses and mood disorders, and the focus of its first oral program is psychosis associated with Parkinson's disease. The company estimates that approximately 50 million people globally live with epilepsy. Ovid also says it seeks to establish multiple sources of potential revenue through clinical and commercial milestones, strategic collaborations and partnerships.
| Product or program | What it is | Stage |
|---|---|---|
| First oral program (KCC2 activator) | Oral small molecule for psychosis associated with Parkinson's disease | clinical-stage |
| Focal onset seizures program | Small molecule for drug-resistant focal onset seizures | clinical-stage |
| Developmental and epileptic encephalopathies program | Small molecule for DEEs, including TSC seizures and infantile spasms | clinical-stage |
| Schizophrenia program | Small molecule for schizophrenia | clinical-stage |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $7.3 million | $566,000 |
| Research and development | $25.6 million | $36.8 million |
| Net income (loss) | -$17.4 million | -$26.4 million |
| Cash from operations | -$38.3 million | -$56.0 million |
| Cash and equivalents | $13.2 million | $26.3 million |
| Short-term investments | $56.5 million | $26.8 million |
Our latest story on this, dated Oct 3, 2025: "Ovid Therapeutics agrees to PIPE financing with $80.8 million in initial gross proceeds". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 3, 2025: "Ovid Therapeutics agrees to PIPE financing with $80.8 million in initial gross proceeds". The story links the filing or release it is based on. Read the story.
Ovid Therapeutics Inc. trades under the ticker OVID on NASDAQ.
Ovid Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1OT; LS:A2DQ8S; LSX:A2DQ8S.
The SEC Central Index Key (CIK) for Ovid Therapeutics Inc. is 1636651. Its filings are on SEC EDGAR.
195,297,857 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Ovid Therapeutics Inc. under United States.
Our directory classifies Ovid Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Ovid Therapeutics Inc. is US6904691010.
aibio.space lists Ovid Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Ovid Therapeutics Inc. is a biopharmaceutical company developing small molecule medicines for brain disorders. Its programs seek to address fundamental biological targets in the brain implicated in neuronal hyperexcitability, such as neurotransmitters and dysregulated ion channels.
First oral program (KCC2 activator): Oral small molecule for psychosis associated with Parkinson's disease Stage: clinical-stage.
Focal onset seizures program: Small molecule for drug-resistant focal onset seizures Stage: clinical-stage.
$7.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported a financing. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Filed documents for a merger or acquisition. SEC Form PREM14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio